Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis.
AUTOR(ES)
Hess, J R
RESUMO
The pharmacokinetics of ceforanide were evaluated in 11 patients with end stage renal disease (creatinine clearance less than 5 ml/min). A single intravenous dose of 750 mg/m2 produced peak plasma concentrations of 123 +/- 29 microgram/ml. The plasma half-life (T 1/2) of the drug was 19.1 +/- 2.5 h. A 5.5 h hemodialysis session removed 53% of the drug and reduced the T 1/2 to 5 +/- 0.7 h. Plasma concentrations greater than 10 microgram/m2 were maintained without adverse effects with a 1.5-g/m2 dose administered three times a week for 2 weeks.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=283766Documentos Relacionados
- Pharmacokinetics of Cefaclor in Patients with End Stage Renal Disease and During Hemodialysis
- Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.
- Pharmacokinetics of moxalactam in patients with renal failure and during hemodialysis.
- Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.
- Intradialytic Administration of Daptomycin in End Stage Renal Disease Patients on Hemodialysis
